Outcomes in patients with active lupus nephritis requiring immunosuppressives who never received cyclophosphamide

Journal of Rheumatology

Volumn 34, Issue 7, 2007, Pages 1491-1496

  Urowitz, Murray B ^a,c   Ibañez, Dominique ^b   Ali, Yaser ^a   Gladman, Dafna D ^a  

^a UNIVERSITY OF TORONTO   (Canada)

^b Centre for Prognosis Studies in the Rheumatic Diseases   (Canada)

^c TORONTO WESTERN HOSPITAL   (Canada)

Author keywords

Cyclophosphamide; Lupus nephritis; Outcomes immunosuppressive agents; Systemic lupus erythematosus

Indexed keywords

ANTIMETABOLITE; CYCLOPHOSPHAMIDE; IMMUNOSUPPRESSIVE AGENT;

ADULT; ARTICLE; CANADA; COHORT ANALYSIS; CYTOTOXICITY; FEMALE; HUMAN; KIDNEY FAILURE; LUPUS ERYTHEMATOSUS NEPHRITIS; MAJOR CLINICAL STUDY; MALE; MORTALITY; OUTCOMES RESEARCH; PRIORITY JOURNAL; RELAPSE;

ADULT; AZATHIOPRINE; COHORT STUDIES; CYCLOPHOSPHAMIDE; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LUPUS NEPHRITIS; MALE; METHOTREXATE; MYCOPHENOLIC ACID; PROGNOSIS; SEVERITY OF ILLNESS INDEX; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 34447518980     PISSN: 0315162X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (29)

1. Urowitz MB, Ibanez D, Gladman D. Changing outcomes in systemic lupus erythematosus over 35 years (abstract). Arthritis Rheum 2005;52 Suppl:S725.
2. McLaughlin J, Gladman DD, Urowitz MB, Bombardier CB, Farewell VT, Cole E. Renal biopsy in SLE. II: Survival analyses according to biopsy results. Arthritis Rheum 1991;34:1268-73.
3. Abu-Shakra M, Urowitz MB, Gladman DD, Gough J. Mortality studies in systemic lupus erythematosus. Results from a single centre. II. Predictor variables for mortality. J Rheumatol 1995;22:1265-70.
4. Steinberg AD, Kaltreider HB, Staples PJ, Goetzl EJ, Talal N, Decker JL. Cyclophosphamide in lupus nephritis: a controlled trial. Ann Intern Med 1971;75:165-71.
5. Carette S, Klippel JH, Decker JL, et al. Controlled studies of oral immunosuppressive drugs in lupus nephritis. A long-term follow-up. Ann Intern Med 1983;99:1-8.
6. Balow JE, Austin HA III, Muenz LR, et al. Effect of treatment on the evolution of renal abnormalities in lupus nephritis. N Engl J Med 1984;311:491-5.
7. Austin HA III, Klippel JH, Balow JE, et al. Therapy of lupus nephritis. Controlled trial of prednisone and cytotoxic drugs. N Engl J Med 1986;314:614-9.
8. Steinberg AD, Steinberg SC. Long-term preservation of renal function in patients with lupus nephritis receiving treatment that includes cyclophosphamide versus those treated with prednisone only. Arthritis Rheum 1991;34:945-50.
9. Boumpas DT, Austin HA III, Vaughn EM, et al. Controlled trial of pulse methylprednisolone versus two regimens of pulse cyclophosphamide in severe lupus nephritis. Lancet 1992;340:741-5.
10. Gourley MF, Austin HA III, Scott D, et al. Methylprednisolone and cyclophosphamide, alone or in combination, in patients with lupus nephritis. A randomized, controlled trial. Ann Intern Med 1996;125:549-57.
11. Illei GG, Austin HA, Crane M, et al. Combination therapy with pulse cyclophosphamide plus pulse methylprednisolone improves long-term renal outcome without adding toxicity in patients with lupus nephritis. Ann Intern Med 2001;135:248-57.
12. Illei GG, Takada K, Parkin D, et al. Renal flares are common in patients with severe proliferative lupus nephritis treated with pulse immunosuppressive therapy: long-term followup of a cohort of 145 patients participating in randomized controlled studies. Arthritis Rheum 2002;46:995-1002.
13. Felson DT, Anderson J. Evidence for the superiority of immunosuppressive drugs and prednisone over prednisone alone in lupus nephritis. Results of a pooled analysis. N Engl J Med 1984;311:1528-33.
14. Mok CC, Ying KY, Tang S, et al. Predictors and outcome of renal flares after successful cyclophosphamide treatment for diffuse proliferative glomerulonephritis. Arthritis Rheum 2004;50:2559-68.
15. Bansal VK, Beto JA. Treatment of lupus nephritis: a meta-analysis of clinical trials. Am J Kidney Dis 1997;29:193-9.
16. Flanc RS, Roberts MA, Strippoli GF, Chadban SJ, Kerr PG, Atkins RC. Treatment of diffuse proliferative lupus nephritis: a meta-analysis of randomized controlled trials. Am J Kidney Dis 2004;43:197-208.
17. Urowitz MB, Gladman DD, Abu-Shakra M, Farewell VT. Mortality studies in systemic lupus erythematosus. Results from a single centre. III. Improved survival over 24 years. J Rheumatol 1997;24:1061-5.
18. Urowitz MB, Gladman DD. Contributions of observational cohort studies in systemic lupus erythematosus: the University of Toronto Lupus Clinic experience. Rheum Dis Clin North Am 2005;31:211-21.
19. Ioannidis JPA, Boki KA, Katsorida EM, et al. Remission, relapse and reremission of proliferative lupus nephritis treated with cyclophosphamide. Kidney Int 2000;57:258-64.
20. Boumpas DT, Austin HA III, Fessler BJ, Balow JE, Klippel JH, Lockshin MD. Systemic lupus erythematosus: emerging concepts. Part 1. Renal, neuropsychiatric, cardiovascular, pulmonary and hematologic disease. Ann Intern Med 1995;122:940-50.
21. Klippel JH. Indications for, and use of, cytotoxic agents in SLE. Baillieres Clin Rheumatol 1998;12:511-27.
22. MacGowan JR, Ellis S, Griffiths M, Isenberg DA. Retrospective analysis of outcome in a cohort of patients with lupus nephritis treated between 1977 and 1999. Rheumatology Oxford 2002;41:981-7.
23. Rahman P, Urowitz MB, Gladman DD. Cytotoxic therapy in systemic lupus erythematosus: experience from a single centre. Medicine 1997;76:432-7.
24. Urowitz MB, Ibanez D, Ali Y, Gladman D. Outcomes in patients with active lupus nephritis requiring immunosuppressives who never received cyclophosphamide (abstract). Arthritis Rheum 2005;52 Suppl:S383.
25. Mok CC, Lai KN. Mycophenolate mofetil in lupus glomerulonephritis. Am J Kidney Dis 2003;40:447-57.
26. Ginzler EM, Dooley MA, Aranow C, et al. Mycophenolate mofetil or intravenous cyclophosphamide for lupus nephritis. N Engl J Med 2005;353:2219-28.
27. Contreras G, Pardo V, Leclercq B, et al. Sequential therapies for proliferative lupus nephritis. N Engl J Med 2004;350:971-80.
28. Grootscholten C, Ligtenberg G, Hagen EC, et al. Azathioprine/ methylprednisolone versus cyclophosphamide in proliferative lupus nephritis. A randomized controlled trial. Kidney Int 2006;70:732-42.
29. Grootscholten C, Bajema IM, Florquin S, et al. Treatment with cyclophosphamide delays the progression of chronic lesions more effectively than does treatment with azathioprine plus methylprednisolone in patients with proliferative lupus nephritis. Arthritis Rheum 2007;56:924-37.